Literature DB >> 20444533

[Consensus document on the diagnosis, treatment and prevention of tuberculosis].

Julià González-Martín1, José María García-García, Luis Anibarro, Rafael Vidal, Jaime Esteban, Rafael Blanquer, Santiago Moreno, Juan Ruiz-Manzano.   

Abstract

Pulmonary TB should be suspected in patients with respiratory symptoms longer than 2-3 weeks. Immunosuppression may modify clinical and radiological presentation. Chest X-ray shows very suggestive, albeit sometimes atypical, signs of TB. Complex radiological tests (CT scan, MR) are more useful in extrapulmonary TB. At least 3 serial representative samples of the clinical location are used for diagnosis whenever possible. Bacilloscopy and liquid medium cultures are indicated in all cases. Genetic amplification techniques are coadjuvant in moderate or high TB suspicion. Administration of isoniazid, rifampicin, ethambutol and pyrazinamide (HREZ) for 2 months and HR for 4 additional months is recommended in new cases of TB, except in cases of meningitis in which treatment should continue for up to 12 months and up to 9 months in spinal TB with neurological involvement, and in silicosis. Appropriate adjustments with antiretroviral treatment should be made in HIV patients. Combined therapy is recommended to avoid development of resistance. An antibiogram to first line drugs should be performed in all the initial isolations of new patients. Treatment control is one of the most important activities in TB management. The Tuberculin Skin Test (TST) is positive in TB infection when >or=5mm, and Interferon-Gamma Release Assays (IGRA) are recommended in combination with TT. The standard treatment schedule for infection is 6 months with isoniazid. In pulmonary TB, respiratory isolation is applied for 3 weeks or until 3 negative bacilloscopy samples are obtained. Copyright 2010 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20444533     DOI: 10.1016/j.arbres.2010.02.010

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  21 in total

1.  Risk factors of non-tuberculous mycobacterial lymphadenitis in children: a case-control study.

Authors:  Patricia W Garcia-Marcos; Mercedes Plaza-Fornieles; Ana Menasalvas-Ruiz; Ramon Ruiz-Pruneda; Pedro Paredes-Reyes; Santiago Alfayate Miguelez
Journal:  Eur J Pediatr       Date:  2017-03-06       Impact factor: 3.183

2.  Role of medical thoracoscopy in the treatment of tuberculous pleural effusion.

Authors:  Yu Xiong; Xusheng Gao; Huaiyang Zhu; Caihong Ding; Jian Wang
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

Review 3.  Tuberculosis of the spine. A systematic review of case series.

Authors:  Manuel Fuentes Ferrer; Luisa Gutiérrez Torres; Oscar Ayala Ramírez; Mercedes Rumayor Zarzuelo; Náyade del Prado González
Journal:  Int Orthop       Date:  2011-11-25       Impact factor: 3.075

4.  Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Authors:  Dimitrios Vassilopoulos; Stamatoula Tsikrika; Chrisoula Hatzara; Varvara Podia; Anna Kandili; Nikolaos Stamoulis; Emilia Hadziyannis
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

5.  Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study.

Authors:  Víctor Vinuesa; Rafael Borrás; María Luisa Briones; María Ángeles Clari; Vicenta Cresencio; Estela Giménez; Carmen Muñoz; Rosa Oltra; Emilio Servera; Talia Scheelje; Carlos Tornero; David Navarro
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

Review 6.  European policies on tuberculosis prevention in healthcare workers: Which role for BCG? A systematic review.

Authors:  Marco Bo; Carla Maria Zotti
Journal:  Hum Vaccin Immunother       Date:  2016-07-07       Impact factor: 3.452

7.  Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method.

Authors:  Man Zhou; Xuelei Geng; Jun Chen; Xude Wang; Dianbing Wang; Jiaoyu Deng; Zhiping Zhang; Weihua Wang; Xian-En Zhang; Hongping Wei
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

8.  Pantoea agglomerans in immunodeficient patients with different respiratory symptoms.

Authors:  Erika Odilia Flores Popoca; Maximino Miranda García; Socorro Romero Figueroa; Aurelio Mendoza Medellín; Horacio Sandoval Trujillo; Hilda Victoria Silva Rojas; Ninfa Ramírez Durán
Journal:  ScientificWorldJournal       Date:  2012-04-24

9.  Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test.

Authors:  Maria Del Mar Arenas Miras; Carmen Hidalgo-Tenorio; Pilar Jimenez-Gamiz; Juan Jiménez-Alonso
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411

10.  Correlation between tuberculin skin test and IGRAs with risk factors for the spread of infection in close contacts with sputum smear positive in pulmonary tuberculosis.

Authors:  Maria Luiza de Souza-Galvão; Irene Latorre; Neus Altet-Gómez; María Ángeles Jiménez-Fuentes; Celia Milà; Jordi Solsona; Maria Asunción Seminario; Adela Cantos; Juan Ruiz-Manzano; José Domínguez
Journal:  BMC Infect Dis       Date:  2014-05-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.